The Bugs That Make Urolithin A: Why You Need the Right Gut Bacteria

By the Flore Clinical Editorial team — Reviewed against primary literature

Every study referenced below is cited with its primary source and linked to PubMed. Where the human evidence is early-stage, we say so — and we keep claims to what the data supports. This article is written for clinicians and informed patients; it is educational and is not medical advice.

Few microbiome-derived metabolites have moved from obscurity to clinical interest as quickly as Urolithin A (UA). It is a postbiotic — a compound your own cells cannot synthesize and that you do not obtain directly from food. Instead, it is manufactured in the colon by specific gut bacteria acting on dietary ellagitannins and ellagic acid, the polyphenols concentrated in pomegranate, walnuts, raspberries, and strawberries.

The clinically relevant catch is this: the conversion is not universal. A patient can eat pomegranate every day and produce little to no Urolithin A if their microbiome lacks the responsible organisms. UA is, in the most literal sense, a metabolite you have to be equipped to make. This article covers what UA is, the human evidence for why it matters, why roughly two-thirds of people are poor producers, the specific bacteria responsible, and how a microbiome-tested approach reframes the conversation from "eat more pomegranate" to "assess, then support."

What Urolithin A Actually Is

Ellagitannins are large polyphenols. They are not absorbed intact; in the gut they hydrolyze to ellagic acid, which is itself poorly bioavailable. Ellagic acid that reaches the colon is then subjected to a sequence of microbial reactions — chiefly lactone-ring cleavage, decarboxylation, and a series of regiospecific dehydroxylations — that progressively strip hydroxyl groups to yield the urolithin series: Uro-M5 → Uro-M6 → Uro-C, and ultimately Urolithin A (Uro-A) or its isomer isourolithin A (IsoUro-A) and Urolithin B.^[1][5] Urolithin A is the most studied and, on current evidence, the most biologically active member of the family.

The key conceptual point for the clinic: UA is a postbiotic produced on-site by the microbiome, not a nutrient delivered by the diet. The food supplies the substrate; the bacteria supply the conversion.

From the plate to the mitochondria — who does what

🍇

Dietary ellagitannins

Pomegranate, walnuts, berries → hydrolyzed to ellagic acid

→

🦠

Gut bacteria convert it

Multi-step dehydroxylation by specific colonic species

→

🧪

Urolithin A

The bioavailable postbiotic enters circulation

→

⚡

Mitophagy

Clearance of damaged mitochondria → cellular health

Why It Matters: Mitophagy and Mitochondrial Health

The best-characterized mechanism of UA is the induction of mitophagy — the selective autophagic clearance of dysfunctional mitochondria. Mitochondrial quality control declines with age; damaged organelles accumulate, ATP output falls, and reactive oxygen species rise. By promoting the removal of compromised mitochondria, UA supports the renewal of the mitochondrial pool, which is the rationale behind its study in muscle function and healthy aging.

Importantly, this is one of the few microbiome metabolites with randomized, placebo-controlled human data, largely from the Mitopure/Amazentis research line:

• First-in-human safety and mechanism (Nat Metab, 2019). In healthy, sedentary older adults, oral UA was safe, bioavailable in plasma, and induced a molecular signature of improved mitochondrial and cellular health — modulating plasma acylcarnitines and skeletal-muscle mitochondrial gene expression.^[6]
• Older adults, muscle endurance (JAMA Netw Open, 2022). A 4-month randomized trial in adults aged 65–90 found that 1,000 mg/day UA significantly improved muscle endurance (contractions to fatigue) in hand and leg muscles versus placebo, and lowered plasma acylcarnitines, ceramides, and C-reactive protein. The primary endpoints (6-minute walk distance and maximal ATP production) showed numerical but not statistically significant improvement.^[7]
• Middle-aged adults, strength and performance (Cell Rep Med, 2022). A 4-month randomized trial reported gains in muscle strength and clinically meaningful improvements in aerobic endurance, alongside reduced plasma acylcarnitines and C-reactive protein and increased expression of mitophagy/mitochondrial proteins in skeletal muscle.^[8]

An honest read of the evidence: the mitophagy mechanism and the safety profile are well established; the functional human signal is genuine but modest, with several primary endpoints missing significance. These are studies of function and biomarkers in generally healthy adults — not disease treatment. UA is a dietary supplement; it is not approved to diagnose, treat, cure, or prevent any disease, and nothing here should be read as a therapeutic claim.

Urolithin A claims — how solid is the human evidence?

🛡️ Safety & bioavailability Well supported

⚡ Mitophagy / mitochondrial gene signature Well supported

💪 Muscle endurance & strength Randomized (modest)

🔥 Lower inflammatory biomarkers (CRP, acylcarnitines) Moderate

⏳ Broader healthy-aging / longevity outcomes Emerging

The Catch: Most People Are Poor Producers

This is the part that changes the clinical conversation. Whether a person converts ellagic acid to Urolithin A is governed by their microbiome, and individuals sort into three reproducible urolithin metabotypes:

• Metabotype A (UM-A) — produces Uro-A (and its precursors) but not IsoUro-A or Uro-B.
• Metabotype B (UM-B) — produces Uro-A plus IsoUro-A and/or Uro-B.
• Metabotype 0 (UM-0) — produces essentially no final urolithins; ellagic acid passes through largely unconverted.

In Western populations the distribution is roughly UM-A ~40%, UM-B ~10%, and UM-0 ~50%, and metabotype shifts with age — the UM-A share tends to fall and UM-B rise over the lifespan.^[1] Practically, this means that only about one-third of people robustly produce Urolithin A, and a large fraction produce little to none. For a UM-0 patient, "eat more pomegranate" is close to a null intervention — the substrate arrives but the conversion machinery is absent.

The Bugs That Make Urolithin A

UA production is not the work of a single organism. It is a multi-step, multi-species relay, and being precise about which organism catalyzes which step matters — both scientifically and for honest claims. The two genera with the clearest experimental evidence for the early steps are Gordonibacter and Ellagibacter (both members of the Eggerthellaceae family); Enterocloster bolteae has been implicated in the terminal dehydroxylations that yield the final urolithins.

Gordonibacter — the initiator

Two human gut species, Gordonibacter pamelaeae and Gordonibacter urolithinfaciens, were among the first organisms shown to convert ellagic acid into urolithin precursors. They drive the early intermediate steps, generating Uro-M5, Uro-M6, and Uro-C, but on their own typically stop short of the final Uro-A — completion requires additional members of the community or in-vivo conditions.^[2][3]

Ellagibacter isourolithinifaciens — the isomer-maker

Ellagibacter isourolithinifaciens, described as a new genus in 2018, also metabolizes ellagic acid through the intermediate series and is notable for its capacity to produce isourolithin A — the metabolite that characterizes metabotype B. Its presence is part of what distinguishes UM-B from UM-A individuals.^[4]

Enterocloster bolteae — the finisher

Enterocloster bolteae (formerly Clostridium bolteae) does not appear to attack ellagic acid directly. Instead, it has been identified as catalyzing the terminal dehydroxylations (at the 9- and 10-positions) that convert intermediates such as Uro-C and IsoUro-A into the final products Uro-A and Uro-B. In other words, it tends to complete a relay that Gordonibacter or Ellagibacter began — which is why metabotype is best understood as a property of the whole community, not one strain.^[5]

At a glance: the organisms and their role in the pathway

The relay model is why metabotype is a community property. A patient may carry the initiator but lack the finisher, or vice versa — and produce little usable Urolithin A either way. Superscripts map to the numbered references below.

The Dietary Substrate — Necessary but Not Sufficient

The diet side is straightforward: the richest ellagitannin sources are pomegranate, walnuts, and the Rubus/Fragaria berries. But every one of these depends on microbial conversion to do anything as Urolithin A. The substrate is necessary; it is not sufficient.

Content figures are relative and vary widely by cultivar, ripeness, and preparation. The constant across every row is the dependence on the microbiome.

The Clinical and Flore Angle: Assess, Then Support

For clinicians, Urolithin A is a clean illustration of why microbiome composition, not just diet, determines outcome — and why a tested, personalized approach beats blanket advice. A patient counseled to "eat pomegranate for healthy aging" who happens to sit in metabotype 0 will derive little from the substrate alone. The clinically useful questions are different: Is this patient a producer? What does their community carry? And how do we pair the right diet with a microbiome that can act on it?

This is the core of the Flore Clinical approach: sequence the patient, read what their microbiome actually shows, and formulate against it rather than against a generic protocol. In the context of UA specifically, that means three honest moves:

• Assess producer status. Metabotype and the presence of conversion-relevant taxa are read from the patient's own microbiome data rather than assumed.
• Support a UA-favorable community. A personalized formula is built from the patient's data, drawing on up to 68 curated strains and 40+ prebiotics to support a diverse community and the conditions in which the conversion pathway can operate.
• Pair diet with the bugs. Ellagitannin-rich foods are positioned as the substrate they are — useful in proportion to the patient's capacity to convert them.

A claim we will not make: Flore formulas are built from each patient's data and are not represented as "adding Gordonibacter" or any specific UA-producing organism. The clinical value is in assessment plus community support plus substrate pairing — not in a marketing claim that a product manufactures Urolithin A. Where a patient is a non-producer, that is itself actionable information, and exogenous UA (e.g., Mitopure-type postbiotic supplementation) is the route that bypasses metabotype entirely; that is a separate product category from anything Flore sells.

For the data behind the personalized model, see The Evidence and what nine years of microbiome data now lets us tell clinicians. For the broader category context, our overview of postbiotics in microbiome medicine places urolithins alongside SCFAs and equol. Clinicians can review the workflow on the For Providers page or get involved through peer review and research partnership.

The Bottom Line

Urolithin A is one of the strongest current examples of a postbiotic with real human evidence — and one of the clearest cases where the diet alone does not predict the result. The substrate comes from pomegranate, walnuts, and berries; the metabolite comes from a cooperative relay of gut bacteria led by Gordonibacter, branched by Ellagibacter, and finished by organisms such as Enterocloster bolteae. Because only about a third of people robustly run that relay, the clinically meaningful step is to assess producer status from the patient's own microbiome, support a community that can convert, and pair the diet accordingly. See how the personalized model works for your patients →

Frequently Asked Questions

Is Urolithin A found in food?

No. Foods such as pomegranate, walnuts, raspberries, and strawberries supply ellagitannins and ellagic acid, but Urolithin A itself is produced in the colon by specific gut bacteria acting on those precursors. Without the responsible microbiome, dietary intake yields little to no Urolithin A.

Why can some people not produce Urolithin A?

Conversion depends on carrying the right bacteria. Individuals sort into three urolithin metabotypes — A (produces Uro-A), B (also produces isourolithin A / Uro-B), and 0 (essentially no final urolithins). In Western populations roughly half are near metabotype 0, so only about one-third are robust Urolithin A producers, and metabotype shifts with age.

Which gut bacteria make Urolithin A?

It is a multi-step relay. Gordonibacter pamelaeae and Gordonibacter urolithinfaciens drive the early conversion of ellagic acid to intermediates; Ellagibacter isourolithinifaciens contributes intermediate steps and produces isourolithin A; and Enterocloster bolteae has been implicated in the terminal dehydroxylations that yield final Urolithin A and Urolithin B. A diverse community matters more than any single strain.

What is Urolithin A supposed to do?

Its best-studied action is inducing mitophagy — clearing dysfunctional mitochondria — which underlies its study in mitochondrial health, cellular energy, and muscle endurance and strength in older and middle-aged adults. The evidence is for function and biomarkers in generally healthy people, not for treating disease.

If a patient cannot produce Urolithin A, what are the options?

Two distinct paths. Supporting a more UA-favorable, diverse community (informed by microbiome testing) addresses the conversion capacity over time. Alternatively, exogenous Urolithin A supplementation (such as Mitopure-type postbiotic products) bypasses metabotype entirely by delivering the metabolite directly. These are different categories, and which is appropriate depends on the patient and clinical context.

Does Flore add Urolithin A-producing bacteria to its formulas?

Flore is working with our clinical partners to establish protocols and formulas that promote an environment where specific Urolithin A-producing organisms can fluorish. The clinical value is in assessing producer status, supporting a diverse community in which the conversion pathway can operate, and pairing that with ellagitannin-rich foods.

References

1. Tomás-Barberán FA, González-Sarrías A, García-Villalba R, et al. Urolithins, the rescue of "old" metabolites to understand a "new" concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. Mol Nutr Food Res. 2017;61(1):1500901. doi:10.1002/mnfr.201500901. PubMed
2. Selma MV, Tomás-Barberán FA, Beltrán D, García-Villalba R, Espín JC. Gordonibacter urolithinfaciens sp. nov., a urolithin-producing bacterium isolated from the human gut. Int J Syst Evol Microbiol. 2014;64(Pt 7):2346–2352. doi:10.1099/ijs.0.055095-0. PubMed
3. Selma MV, Beltrán D, García-Villalba R, Espín JC, Tomás-Barberán FA. Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct. 2014;5(8):1779–1784. doi:10.1039/c4fo00092g. PubMed
4. Beltrán D, Romo-Vaquero M, Espín JC, Tomás-Barberán FA, Selma MV. Ellagibacter isourolithinifaciens gen. nov., sp. nov., a new member of the family Eggerthellaceae, isolated from human gut. Int J Syst Evol Microbiol. 2018;68(5):1707–1712. doi:10.1099/ijsem.0.002735. PubMed
5. Iglesias-Aguirre CE, García-Villalba R, Beltrán D, et al. Gut Bacteria Involved in Ellagic Acid Metabolism To Yield Human Urolithin Metabotypes Revealed. J Agric Food Chem. 2023;71(9):4029–4035. doi:10.1021/acs.jafc.2c08889. PubMed
6. Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019;1(6):595–603. doi:10.1038/s42255-019-0073-4. PubMed
7. Liu S, D'Amico D, Shankland E, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(1):e2144279. doi:10.1001/jamanetworkopen.2021.44279. PubMed
8. Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med. 2022;3(5):100633. doi:10.1016/j.xcrm.2022.100633. PubMed

These statements have not been evaluated by the Food and Drug Administration. Flore Clinical products are not intended to diagnose, treat, cure, or prevent any disease. Urolithin A supplementation referenced here is a dietary supplement category and is not a Flore product. Cited human trials were conducted in generally healthy adults and report functional and biomarker endpoints, several of which did not reach statistical significance; bacteriology citations are isolation/characterization and mechanistic studies. This article is educational and is not a substitute for individualized clinical judgment.

← Back to Journal